Gland Pharma tanks 20%,

Gland Pharma tanks 20%, hits record low on weak Q4 results

Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.